Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VEGFA | P15692 | 7/20 | 0.48 |
| ▸ | EPAS1 | Q99814 | 17/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18048476 | 0.81 | EPAS1 (0.64) | VEGFAEPAS1 | |
| SCHEMBL20253145 | 0.72 | EPAS1 (0.65) | VEGFAEPAS1 | |
| SCHEMBL16555759 | 0.67 | EPAS1 (0.63) | VEGFAEPAS1 | |
| SCHEMBL18036735 | 0.67 | EPAS1 (0.63) | VEGFAEPAS1 | |
| SCHEMBL18036738 | 0.65 | VEGFA (1.00) | VEGFAEPAS1 | |
| SCHEMBL16555912 | 0.65 | VEGFA (1.00) | VEGFAEPAS1 | |
| SCHEMBL20253146 | 0.64 | EPAS1 (0.53) | VEGFAEPAS1 | |
| SCHEMBL16560836 | 0.62 | VEGFA (0.86) | VEGFAEPAS1 | |
| SCHEMBL21005379 | 0.62 | VEGFA (0.86) | VEGFAEPAS1 | |
| SCHEMBL16555574 | 0.62 | EPAS1 (1.00) | VEGFAEPAS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | PELOTON THERAPEUTICS, INC. | 2019-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190282535-A1 | COMBINATION THERAPY OF A HIF-2-ALPHA INHIBITOR AND AN IMMUNOTHERAPEUTIC AGENT AND USES THEREOF | HIF1AN, HIF1A, EGLN2 | VEGFA 47/4885EPAS1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.